JP2015508823A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015508823A5 JP2015508823A5 JP2014560041A JP2014560041A JP2015508823A5 JP 2015508823 A5 JP2015508823 A5 JP 2015508823A5 JP 2014560041 A JP2014560041 A JP 2014560041A JP 2014560041 A JP2014560041 A JP 2014560041A JP 2015508823 A5 JP2015508823 A5 JP 2015508823A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- unsubstituted
- alkyl
- alkoxy
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 18
- 125000003545 alkoxy group Chemical group 0.000 claims 15
- 150000001875 compounds Chemical class 0.000 claims 13
- 150000003839 salts Chemical class 0.000 claims 13
- 125000001475 halogen functional group Chemical group 0.000 claims 9
- 125000000623 heterocyclic group Chemical group 0.000 claims 9
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 125000003118 aryl group Chemical group 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 230000001404 mediated effect Effects 0.000 claims 6
- 229910052799 carbon Inorganic materials 0.000 claims 4
- 125000004432 carbon atom Chemical group C* 0.000 claims 4
- -1 —OH Chemical group 0.000 claims 4
- 125000003282 alkyl amino group Chemical group 0.000 claims 3
- 125000004103 aminoalkyl group Chemical group 0.000 claims 3
- 125000001072 heteroaryl group Chemical group 0.000 claims 3
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 2
- 150000001204 N-oxides Chemical class 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 208000024908 graft versus host disease Diseases 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 208000008732 thymoma Diseases 0.000 claims 2
- 125000004398 2-methyl-2-butyl group Chemical group CC(C)(CC)* 0.000 claims 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 206010008609 Cholangitis sclerosing Diseases 0.000 claims 1
- 208000015943 Coeliac disease Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 208000004262 Food Hypersensitivity Diseases 0.000 claims 1
- 206010016946 Food allergy Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010054048 Postoperative ileus Diseases 0.000 claims 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 201000009365 Thymic carcinoma Diseases 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 230000001760 anti-analgesic effect Effects 0.000 claims 1
- 230000003110 anti-inflammatory effect Effects 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000003176 fibrotic effect Effects 0.000 claims 1
- 235000020932 food allergy Nutrition 0.000 claims 1
- 208000006454 hepatitis Diseases 0.000 claims 1
- 231100000283 hepatitis Toxicity 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 208000019423 liver disease Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims 1
- 201000000742 primary sclerosing cholangitis Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 208000010157 sclerosing cholangitis Diseases 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 238000011200 topical administration Methods 0.000 claims 1
- 0 CC(C)(*)c(cc1)ccc1S(Nc1cc(C)n[n]1-c1cccc2ncccc12)(=O)=O Chemical compound CC(C)(*)c(cc1)ccc1S(Nc1cc(C)n[n]1-c1cccc2ncccc12)(=O)=O 0.000 description 5
- DMBYVPJRFYFHOU-UHFFFAOYSA-N CC(C)(C)c(c(Cl)c1)ccc1S(Nc1cc(C)n[n]1-c1cccc2ncccc12)(=O)=O Chemical compound CC(C)(C)c(c(Cl)c1)ccc1S(Nc1cc(C)n[n]1-c1cccc2ncccc12)(=O)=O DMBYVPJRFYFHOU-UHFFFAOYSA-N 0.000 description 1
- KIPMKGUFUYBZGA-UHFFFAOYSA-N CC(C)(C)c(c(F)c1)ccc1S(Nc1cc(C)n[n]1-c(c1cccnc11)ccc1C#N)(=O)=O Chemical compound CC(C)(C)c(c(F)c1)ccc1S(Nc1cc(C)n[n]1-c(c1cccnc11)ccc1C#N)(=O)=O KIPMKGUFUYBZGA-UHFFFAOYSA-N 0.000 description 1
- YGVYVKCOQGHMMH-UHFFFAOYSA-N CC(C)(C)c(c(F)c1)ccc1[S-](Nc1cc(C)n[n]1-c(cc1)c(cccn2)c2c1Br)(O)=O Chemical compound CC(C)(C)c(c(F)c1)ccc1[S-](Nc1cc(C)n[n]1-c(cc1)c(cccn2)c2c1Br)(O)=O YGVYVKCOQGHMMH-UHFFFAOYSA-N 0.000 description 1
- VZIIUQKRPDNTBL-UHFFFAOYSA-N CC(C)(C)c(c(F)cc([S-](Nc1cc(C)n[n]1-c1cccc2ncccc12)(O)=O)c1)c1F Chemical compound CC(C)(C)c(c(F)cc([S-](Nc1cc(C)n[n]1-c1cccc2ncccc12)(O)=O)c1)c1F VZIIUQKRPDNTBL-UHFFFAOYSA-N 0.000 description 1
- WYFAWYCAHJPQOA-UHFFFAOYSA-N CC(C)(C)c(cc1)ccc1S(Nc1cc(C)n[n]1-c(c1ccc2)cccc1[n+]2[O-])(=O)=O Chemical compound CC(C)(C)c(cc1)ccc1S(Nc1cc(C)n[n]1-c(c1ccc2)cccc1[n+]2[O-])(=O)=O WYFAWYCAHJPQOA-UHFFFAOYSA-N 0.000 description 1
- CKFUDMSXTVDDAS-UHFFFAOYSA-N CC(C)(C)c(cc1)ccc1S(Nc1cc(C)n[n]1-c(c1cccnc11)ccc1Br)(=O)=O Chemical compound CC(C)(C)c(cc1)ccc1S(Nc1cc(C)n[n]1-c(c1cccnc11)ccc1Br)(=O)=O CKFUDMSXTVDDAS-UHFFFAOYSA-N 0.000 description 1
- HTLOMTTXDXVERD-UHFFFAOYSA-N CC(C)(C)c(cc1)ccc1S(Nc1cc(C)n[n]1-c(c1cccnc11)ccc1C#N)(=O)=O Chemical compound CC(C)(C)c(cc1)ccc1S(Nc1cc(C)n[n]1-c(c1cccnc11)ccc1C#N)(=O)=O HTLOMTTXDXVERD-UHFFFAOYSA-N 0.000 description 1
- AVFDSWSKFKZWDB-UHFFFAOYSA-N CC(C)(C)c(cc1)ccc1S(Nc1cc(C)n[n]1-c(cc1)c(cccn2)c2c1F)(=O)=O Chemical compound CC(C)(C)c(cc1)ccc1S(Nc1cc(C)n[n]1-c(cc1)c(cccn2)c2c1F)(=O)=O AVFDSWSKFKZWDB-UHFFFAOYSA-N 0.000 description 1
- WRJDCGGOVQVUIM-UHFFFAOYSA-N CC(C)Oc(c(F)c1)ccc1S(Nc1cc(C)n[n]1-c1c(cccn2)c2ccc1)(=O)=O Chemical compound CC(C)Oc(c(F)c1)ccc1S(Nc1cc(C)n[n]1-c1c(cccn2)c2ccc1)(=O)=O WRJDCGGOVQVUIM-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261604998P | 2012-02-29 | 2012-02-29 | |
| US61/604,998 | 2012-02-29 | ||
| PCT/US2013/028328 WO2013130811A1 (en) | 2012-02-29 | 2013-02-28 | Pyrazol-1-yl benzene sulfonamides as ccr9 antagonists |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017152743A Division JP6322325B2 (ja) | 2012-02-29 | 2017-08-07 | Ｃｃ９アンタゴニストとしてのピラゾール−１−イルベンゼンスルホンアミド |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015508823A JP2015508823A (ja) | 2015-03-23 |
| JP2015508823A5 true JP2015508823A5 (enExample) | 2016-09-01 |
| JP6249966B2 JP6249966B2 (ja) | 2017-12-20 |
Family
ID=47844528
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014560041A Active JP6249966B2 (ja) | 2012-02-29 | 2013-02-28 | アザ−アリール１ｈ−ピラゾール−１−イルベンゼンスルホンアミド |
| JP2017152743A Active JP6322325B2 (ja) | 2012-02-29 | 2017-08-07 | Ｃｃ９アンタゴニストとしてのピラゾール−１−イルベンゼンスルホンアミド |
| JP2018070806A Active JP6553236B2 (ja) | 2012-02-29 | 2018-04-02 | Ｃｃ９アンタゴニストとしてのピラゾール−１−イルベンゼンスルホンアミド |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017152743A Active JP6322325B2 (ja) | 2012-02-29 | 2017-08-07 | Ｃｃ９アンタゴニストとしてのピラゾール−１−イルベンゼンスルホンアミド |
| JP2018070806A Active JP6553236B2 (ja) | 2012-02-29 | 2018-04-02 | Ｃｃ９アンタゴニストとしてのピラゾール−１−イルベンゼンスルホンアミド |
Country Status (18)
| Country | Link |
|---|---|
| US (5) | US8916601B2 (enExample) |
| EP (3) | EP3738958A1 (enExample) |
| JP (3) | JP6249966B2 (enExample) |
| KR (1) | KR102083693B1 (enExample) |
| CN (2) | CN104520288B (enExample) |
| AU (3) | AU2013225938B2 (enExample) |
| BR (1) | BR112014021148B1 (enExample) |
| CA (1) | CA2865714C (enExample) |
| DK (2) | DK2820006T3 (enExample) |
| ES (2) | ES2645617T3 (enExample) |
| HK (1) | HK1206012A1 (enExample) |
| MX (2) | MX372722B (enExample) |
| PL (2) | PL2820006T3 (enExample) |
| PT (1) | PT3263564T (enExample) |
| RU (1) | RU2627268C2 (enExample) |
| SG (2) | SG11201405241VA (enExample) |
| WO (1) | WO2013130811A1 (enExample) |
| ZA (1) | ZA201406432B (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10827315B2 (en) * | 2006-04-07 | 2020-11-03 | Groupon, Inc. | Facilitating user interactions based on proximity |
| US9100454B2 (en) | 2006-04-07 | 2015-08-04 | Groupon, Inc. | Method and system for enabling the creation and maintenance of proximity-related user groups |
| DK2820006T3 (da) * | 2012-02-29 | 2017-11-06 | Chemocentryx Inc | Pyrazol-1-yl benzen sulfonamider som ccr9 antagonister |
| UY35165A (es) | 2012-12-04 | 2014-06-30 | Takeda Pharmaceutical | Método profiláctico o terapéutico para el síndrome de sjogren |
| GB201308978D0 (en) | 2013-05-17 | 2013-07-03 | Imp Innovations Ltd | Method for producing polymers and block copolymers |
| CN105960237B (zh) * | 2013-12-02 | 2020-03-31 | 凯莫森特里克斯股份有限公司 | Ccr6化合物 |
| JP2017501145A (ja) * | 2013-12-23 | 2017-01-12 | ノージン ビーブイ | Ｃｃｒ９調節因子として有用な化合物 |
| MA40592A (fr) | 2014-10-06 | 2016-04-14 | Chemocentryx Inc | Compositions et méthodes pour le traitement d'une maladie inflammatoire de l'intestin à l'aide d'une polythérapie à base d'inhibiteurs à petites molécules de récepteur 9 de chimiokine c-c (ccr9) et d'anticorps bloquants anti-intégrine alpha4beta7 |
| GB201515350D0 (en) | 2015-08-28 | 2015-10-14 | Econic Technologies Ltd | Method for preparing polyols |
| BR112018014666B1 (pt) * | 2016-01-20 | 2024-01-02 | Chemocentryx, Inc | Compostos de 2-oxindol, seu uso e composição farmacêutica |
| RU2768479C2 (ru) * | 2016-06-13 | 2022-03-24 | Хемоцентрикс, Инк. | Способы лечения рака поджелудочной железы |
| CN110636846B (zh) * | 2017-05-17 | 2023-05-16 | 艾库斯生物科学有限公司 | 用于治疗癌症相关疾病的喹唑啉吡唑衍生物 |
| AU2019312296B2 (en) * | 2018-07-27 | 2025-05-29 | Arcus Biosciences, Inc. | Pyridone A2R antagonists |
| US20240281033A1 (en) * | 2018-10-24 | 2024-08-22 | Screen Skinz, Inc. | Screen protector with engraved image |
| US20200319677A1 (en) * | 2018-10-24 | 2020-10-08 | Clay Canning | Screen protector with engraved image |
| KR102890201B1 (ko) | 2019-07-10 | 2025-11-24 | 케모센트릭스, 인크. | Pd-l1 억제제로서의 인단 |
| EP3805206B1 (en) * | 2019-10-08 | 2026-08-05 | Novaled GmbH | Compound and an organic semiconducting layer, an organic electronic device, a display device and a lighting device comprising the same |
| ES3068390T3 (en) * | 2019-10-16 | 2026-05-29 | Chemocentryx Inc | Heteroaryl-biphenyl amides for the treatment of pd-l1 diseases |
| AU2020368392B2 (en) | 2019-10-16 | 2026-01-08 | Chemocentryx, Inc. | Heteroaryl-biphenyl amines for the treatment of PD-L1 diseases |
| US10792360B1 (en) | 2019-11-21 | 2020-10-06 | Chemocentryx, Inc. | Compositions and methods for treating inflammatory bowel disease using CCR9 inhibitor and anti-TNF-alpha blocking antibodies |
| TWI904146B (zh) * | 2020-03-31 | 2025-11-11 | 美商卡默森屈有限公司 | 使用ｃｃｒ９抑制劑及抗ｉｌ-２３阻斷抗體治療發炎性腸道疾病的組成物及方法 |
| SMT202500447T1 (it) | 2021-11-02 | 2026-01-12 | Flare Therapeutics Inc | Agonisti inversi di pparg e loro usi |
| KR102584607B1 (ko) | 2023-01-19 | 2023-10-04 | 아주대학교산학협력단 | 1h-피라졸-3-아마이드계 화합물 유도체를 포함하는 염증성 피부질환 예방 또는 치료용 조성물 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
| US3817837A (en) | 1971-05-14 | 1974-06-18 | Syva Corp | Enzyme amplification assay |
| US3939350A (en) | 1974-04-29 | 1976-02-17 | Board Of Trustees Of The Leland Stanford Junior University | Fluorescent immunoassay employing total reflection for activation |
| US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
| US4166452A (en) | 1976-05-03 | 1979-09-04 | Generales Constantine D J Jr | Apparatus for testing human responses to stimuli |
| US4256108A (en) | 1977-04-07 | 1981-03-17 | Alza Corporation | Microporous-semipermeable laminated osmotic system |
| US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
| US4277437A (en) | 1978-04-05 | 1981-07-07 | Syva Company | Kit for carrying out chemically induced fluorescence immunoassay |
| US4265874A (en) | 1980-04-25 | 1981-05-05 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
| US4366241A (en) | 1980-08-07 | 1982-12-28 | Syva Company | Concentrating zone method in heterogeneous immunoassays |
| US5120643A (en) | 1987-07-13 | 1992-06-09 | Abbott Laboratories | Process for immunochromatography with colloidal particles |
| US6159686A (en) | 1992-09-14 | 2000-12-12 | Sri International | Up-converting reporters for biological and other assays |
| US5514555A (en) | 1993-03-12 | 1996-05-07 | Center For Blood Research, Inc. | Assays and therapeutic methods based on lymphocyte chemoattractants |
| US6322901B1 (en) | 1997-11-13 | 2001-11-27 | Massachusetts Institute Of Technology | Highly luminescent color-selective nano-crystalline materials |
| US6207392B1 (en) | 1997-11-25 | 2001-03-27 | The Regents Of The University Of California | Semiconductor nanocrystal probes for biological applications and process for making and using such probes |
| US5990479A (en) | 1997-11-25 | 1999-11-23 | Regents Of The University Of California | Organo Luminescent semiconductor nanocrystal probes for biological applications and process for making and using such probes |
| US6326144B1 (en) | 1998-09-18 | 2001-12-04 | Massachusetts Institute Of Technology | Biological applications of quantum dots |
| US6306610B1 (en) | 1998-09-18 | 2001-10-23 | Massachusetts Institute Of Technology | Biological applications of quantum dots |
| US6251303B1 (en) | 1998-09-18 | 2001-06-26 | Massachusetts Institute Of Technology | Water-soluble fluorescent nanocrystals |
| US6294192B1 (en) | 1999-02-26 | 2001-09-25 | Lipocine, Inc. | Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents |
| AU2001273040A1 (en) | 2000-06-27 | 2002-01-08 | Du Pont Pharmaceuticals Company | Factor xa inhibitors |
| AU2003248549B2 (en) * | 2002-05-24 | 2010-04-08 | Millennium Pharmaceuticals, Inc. | CCR9 inhibitors and methods of use thereof |
| AU2003298661B2 (en) * | 2002-11-18 | 2007-05-10 | Chemocentryx, Inc. | Aryl sulfonamides |
| TW200510311A (en) * | 2002-12-23 | 2005-03-16 | Millennium Pharm Inc | CCr8 inhibitors |
| SE0301653D0 (sv) * | 2003-06-05 | 2003-06-05 | Astrazeneca Ab | Novel compounds |
| JP2007537275A (ja) * | 2004-05-12 | 2007-12-20 | ケモセントリックス， インコーポレイテッド | アリールスルホンアミド |
| SE0402635D0 (sv) | 2004-10-29 | 2004-10-29 | Astrazeneca Ab | Chemical compounds |
| PL2046762T3 (pl) * | 2006-07-14 | 2011-07-29 | Chemocentryx Inc | Triazolilofenylobenzenosulfonamidy |
| US20100234364A1 (en) * | 2006-07-14 | 2010-09-16 | Arindrajit Basak | Ccr2 inhibitors and methods of use thereof |
| MX2009008425A (es) | 2007-02-06 | 2009-08-17 | Novartis Ag | Derivados de 1-bencensulfonil-1h-indol como inhibidores de la actividad de ccr9. |
| US7776877B2 (en) * | 2007-06-22 | 2010-08-17 | Chemocentryx, Inc. | N-(2-(hetaryl)aryl) arylsulfonamides and N-(2-(hetaryl) hetaryl arylsulfonamides |
| US9315449B2 (en) | 2008-05-15 | 2016-04-19 | Duke University | Substituted pyrazoles as heat shock transcription factor activators |
| DK2820006T3 (da) * | 2012-02-29 | 2017-11-06 | Chemocentryx Inc | Pyrazol-1-yl benzen sulfonamider som ccr9 antagonister |
| MA40592A (fr) * | 2014-10-06 | 2016-04-14 | Chemocentryx Inc | Compositions et méthodes pour le traitement d'une maladie inflammatoire de l'intestin à l'aide d'une polythérapie à base d'inhibiteurs à petites molécules de récepteur 9 de chimiokine c-c (ccr9) et d'anticorps bloquants anti-intégrine alpha4beta7 |
| US9715915B2 (en) | 2014-10-30 | 2017-07-25 | Samsung Electronics Co., Ltd. | Magneto-resistive devices including a free layer having different magnetic properties during operations |
-
2013
- 2013-02-28 DK DK13708633.6T patent/DK2820006T3/da active
- 2013-02-28 ES ES13708633.6T patent/ES2645617T3/es active Active
- 2013-02-28 JP JP2014560041A patent/JP6249966B2/ja active Active
- 2013-02-28 EP EP20178966.6A patent/EP3738958A1/en not_active Withdrawn
- 2013-02-28 PT PT171842057T patent/PT3263564T/pt unknown
- 2013-02-28 SG SG11201405241VA patent/SG11201405241VA/en unknown
- 2013-02-28 PL PL13708633T patent/PL2820006T3/pl unknown
- 2013-02-28 EP EP17184205.7A patent/EP3263564B1/en active Active
- 2013-02-28 DK DK17184205.7T patent/DK3263564T3/da active
- 2013-02-28 MX MX2017002834A patent/MX372722B/es unknown
- 2013-02-28 WO PCT/US2013/028328 patent/WO2013130811A1/en not_active Ceased
- 2013-02-28 KR KR1020147026018A patent/KR102083693B1/ko active Active
- 2013-02-28 HK HK15106465.6A patent/HK1206012A1/xx unknown
- 2013-02-28 MX MX2014010340A patent/MX2014010340A/es not_active Application Discontinuation
- 2013-02-28 CN CN201380022592.0A patent/CN104520288B/zh active Active
- 2013-02-28 SG SG10201700493XA patent/SG10201700493XA/en unknown
- 2013-02-28 BR BR112014021148-5A patent/BR112014021148B1/pt active IP Right Grant
- 2013-02-28 CA CA2865714A patent/CA2865714C/en active Active
- 2013-02-28 PL PL17184205T patent/PL3263564T3/pl unknown
- 2013-02-28 ES ES17184205T patent/ES2816060T3/es active Active
- 2013-02-28 US US13/781,412 patent/US8916601B2/en active Active
- 2013-02-28 AU AU2013225938A patent/AU2013225938B2/en active Active
- 2013-02-28 CN CN201710255210.9A patent/CN107266425B/zh active Active
- 2013-02-28 RU RU2014136216A patent/RU2627268C2/ru active
- 2013-02-28 EP EP13708633.6A patent/EP2820006B1/en active Active
-
2014
- 2014-09-02 ZA ZA2014/06432A patent/ZA201406432B/en unknown
- 2014-11-14 US US14/541,637 patent/US10137120B2/en active Active
-
2017
- 2017-08-07 JP JP2017152743A patent/JP6322325B2/ja active Active
- 2017-11-09 AU AU2017258909A patent/AU2017258909B2/en active Active
-
2018
- 2018-04-02 JP JP2018070806A patent/JP6553236B2/ja active Active
- 2018-10-25 US US16/170,752 patent/US10596163B2/en active Active
-
2019
- 2019-10-10 AU AU2019246848A patent/AU2019246848B2/en not_active Expired - Fee Related
-
2020
- 2020-03-03 US US16/807,891 patent/US20200197386A1/en not_active Abandoned
-
2021
- 2021-10-29 US US17/452,946 patent/US12611404B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2014136216A (ru) | Аза-арил-1Н-пиразол-1-ил-сульфонамиды | |
| JP2014517017A5 (ja) | 化合物、その医薬組成物、及び癌治療用の阻害薬としてのその使用 | |
| RU2017134013A (ru) | Производные желчных кислот в качестве агонистов fxr/tgr5 и способы их применения | |
| RU2017115809A (ru) | Комбинированная терапия ингибиторами с-с хемокинового рецептора 9 (ccr9) и антителами, блокирующими альфа4бета7-интегрин | |
| JP2016525075A5 (enExample) | ||
| RU2014114466A (ru) | ИНДАЗОЛ-3-КАРБОКСАМИДЫ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРОВ СИГНАЛЬНОГО ПУТИ WNT/β-КАТЕНИНА | |
| CN109311812A (zh) | 作为c-MET抑制剂的吡啶酮类化合物 | |
| JP2016540051A5 (enExample) | ||
| JP2017511357A5 (enExample) | ||
| JP2016535784A5 (enExample) | ||
| JP2017514855A5 (enExample) | ||
| JP2009511490A5 (enExample) | ||
| JP2008504304A5 (enExample) | ||
| JP2015503622A5 (enExample) | ||
| JP2008504301A5 (enExample) | ||
| JP2016506368A5 (enExample) | ||
| JP2017509689A5 (enExample) | ||
| JP2016531113A5 (enExample) | ||
| JP2017501236A5 (enExample) | ||
| RU2020112502A (ru) | Циклические динуклеотиды в качестве стимулятора модуляторов генов интерферона | |
| JP2014507464A5 (enExample) | ||
| JP2016535732A5 (enExample) | ||
| JP2016501246A5 (enExample) | ||
| RU2017104856A (ru) | Функционализированные и замещенные индолы в качестве противораковых средств | |
| JP2010501478A5 (enExample) |